Objective: Pharmaceutical cocrystal is a promising tool to enhance solubility and dissolution of poorly soluble drugs.
INTRODUCTION
After oral administration solubility and dissolution rate of drug is crucial factor for sufficient bioavailability of drug. This factor offers main challenge to the formulation scientist for the development and formulation of effective drug. More than 40% of drugs in the development suffers from bioavailability problems owing to poor solubility. Alternative strategies have been introduced to enhance solubility, dissolution rate and bioavailability. These involves salt formation, solid dispersion, cyclodextrin complexation, microemulsification, solubilization, micronization etc. [1] [2] [3] [4] Recently pharmaceutical cocrystals attracted massive attention of formulation experts busy in the formulation develpment. Due to inherent thermodynamic stability of crystalline active pharmaceutical ingredients (API), these are preferred in pharmaceutical industry. Pharmaceutical cocrystals have emerged as effective tool to tailor the physical properties of API like solubility and dissolution along with stability. The principal advantage of this technique is pharmacological effect of drug remain unchanged. [5] [6] [7] Cocrystals are defined as stoichiometric multi-component system united by non-covalent interactions in which two diverse components are solid under ambient conditions. Documented advantages of cocrystals are improved stability against humidity, chemical stability, improved dissolution and bioavaialability and tabletability. Various methods were studied to enhance solubility like hydrotropy, solid dispersion etc. Probably pharmaceutical cocrystals of ZFN have not been reported till date. [8] [9] [10] [11] [12] [13] [14] Zaltoprofen is a nonsteroidal anti-inflammatory propionic acid class drug.It is used in the treatment of acute and chronic inflammation and in the treatment of rheumatoid arthritis. It is practically insoluble in water and associated with side effects like ulcerogenicity, bellyache and indigestion. Moreover, ZFN is weakly ionisable so salt formation is impossible to enhance the solubility of drug. Rapid onset and improved u n c o r r e c t e d p r o o f bioavailability are enviable for analgesics. Hence there is strong scientific and clinical need to prepare novel forms of ZFN possessing modified solubility and dissolution rate which can be formulated for oral administration. Accordingly the present study was aimed to prepare novel pharmaceutical cocrystals of ZFN with improved solubility and dissolution. 15, 16 
MATERIALS AND METHODS

Materials
Zaltoprofen was received as gift sample from ICPA laboratory Ltd. Mumbai (India).
All other chemicals were purchased from the SD Fine Chemicals Mumbai (India). Double distilled water was used throughout the research.
Preparation of cocrystal
Dry grinding method was adopted for the preparation of ZFN cocrystals. Drug and coformers were mixed in different molar ratio (1:1 and 1:2) in mortar and pestle for 45 min to form cocrystals. This was dried an overnight at ambient temperature and stored in tight containers. 17 The 25 coformers were screened for the preparation of cocrystals viz. salicylic acid, nicotinamide, glutaric acid, malonic acid, benzoic acid, tartaric acid, oxalic acid, citric acid, urea, succinic acid, saccharine sodium, Pluronic 68 AR, Magnesium stearate, crotonic acid, P-hydroxy benzoic acid, Caffeine, 3,5 dihydroxy benzoic acid, Piperazine citrate, Cinnamic acid, Adipic acid, Hydroquinone, Isonicotinic acid, Acetamide, Maleic acid, Ascorbic acid.
Evaluation of corystals
Drug content
The cocrystal powder equivalent to 10 mg of drug was accurately weighed and dissolved in 10 ml volumetric flask and volume was adjusted with phosphate buffer pH 6.8. The resulting solution was filtered, suitably diluted and absorbance of the solution was measured at 243 nm. 18 (Shimadzu UV 1800)
Determination of melting point
Melting point of the compounds were determined using digital melting point apparatus (Labtronics Ltd). 
IR spectroscopy
IR spectroscopy was employed to determine the possible interaction between drug and coformers. Samples were mixed with potassium bromide and compressed into discs before scanning between 4000-400 cm-1 with resolution of 4 cm-1 by shimadzu IR Spectrophotometer.
Differential scanning calorimetry
The thermal behavior of drug alone and cocrystal was determined on Mettler Toledo DSC 822e Module. Weighed samples were loaded into aluminum pan before crimping and heated at a rate of 5 °C/min, covering 0 to 300 °C temperature range, under a nitrogen stream. The instrument was calibrated using indium and empty aluminum pan was used as a reference.
Powder X-ray diffraction
The silicon sample holders were utilized to get diffraction patterns of pure ZFN and cocrystal (Bruker D8 Advance Diffractometer). The instrument was equipped with a fine focus X-ray tube and each sample was placed on to a goniometer head that was motorized to permit spinning of the sample during data acquisition.
In vitro dissolution study
Pure ZFN and its cocrystals were subjected to dissolution study by USP type II apparatus (Electrolab, Mumbai, India). Dissolution study was performed in 900 ml of pH 6.8 phosphate buffer at 37±0.5°C and 50 rpm for 60 min. The pure drug and cocrystal equivalent to 80 mg of drug was used for the study. The 5 ml of samples were withdrawn after specified time interval and analyzed by UV spectrophotometer at 243 nm.
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Stability study
The selected cocrystals were subjected to stability study at room temperature and 400C ± 20C with 75% ± 5% RH for 3 months. The sample of 1 gm was placed in epindron tube in stability chamber throughout the stability duration and analyzed after 30 days, 60 days and 90 days interval. The different attributes were studied to u n c o r r e c t e d p r o o f assess the stability viz. drug content, melting point, solubility, in vitro drug release etc.
RESULTS AND DISCUSSION
The 25 coformers were screened to prepare cocrystal with ZFN by dry grinding method. The coformers were selected based on the literature survey and to increase the chances of formation of number of new cocrystals. Among various coformers studied nicotinamide successfully interacted with ZFN, giving novel cocrystal forms.
The obtained ZFN cocrystals were subjected to evaluation and stability study.
Drug content
Drug content of ZFN-NIC 1:1 and 1:2 cocrystals was determined in the phosphate buffer pH 6.8 and obtained 95.87±0.98% and 95.88±1.10% respectively.
Melting point and saturation solubility
Melting points of pure drug, coformers and cocrystals were estimated and reported in Table 1 . In addition saturation solubility of pure drug and cocrystals was also determined and reported in Table 1 . These parameters were used as preliminary screen for cocrystal. Melting points of the ZFN-NIC cocrystals were lower than the pure drug. This may be attributed to multicomponent system and probable formation of cocrystals. The altered melting points might be due to interaction between zaltoprofen and nicotinamide, modified crystallinity of molecules or distinct packing arrangement. This interaction results in altered molecular arrangement which lead to novel crystal forms with distinct physical properties. 20, 21 Solubility of few cocrystals was improved but ZFN-NIC cocrystals exhibited remarkable increase in solubility indicating successful interaction of drug and coformer. However greater solubility was obtained with ZFN-NIC 1:2 cocrystals 
IR spectroscopy
The IR spectrum for pure drug, coformer and ZFN cocrystals was recorded and shown in Figure 1 indicating interaction between drug and coformer. 24 In case of 1:1 cocrystal changes were observed in the peaks corresponding to carboxylic group stretching which was observed at 1634 cm-1, OH stretching at 3000 cm-1 in comparison to drug and NH2 stretch and NH bending at 3450 and 1583 cm1as compared to nicotinmaide whereas 1654 cm-1, 3000 cm-1, 3300 cm-1 and 1583 cm-1 for 1:2 cocrystal respectively.
The new peak at 3450 cm-1 and 3400 cm-1 was observed indicating formation of hydrogen bond between drug and coformer in the ZFN-nicotinamide 1:1 and 1:2 cocrystal prepared by neat grinding method respectively. 25 Similar changes in the IR spectrum of other drugs like piroxicam, hydrochlorothiazide were reported and taken as sign of the cocrystal formation. [26] [27] Hence the changes recorded in the study can be taken as a indicator of the cocrystal formation between the drug and coformer. respectively which is significantly different from the pure drug. Moreover, the peak onset for pure drug was obtained at 131.52°C whereas 102.40°C and 120.02°C for 1:1 and 1:2 cocrystals respectively.
The changes in the thermal properties were reported as evidence for the formation of cocrystal. 29 Hence the present investigation indicates the formation of cocrystal. 
In vitro dissolution study
The dissolution rate plays crucial role in the bioavailability of drugs with poor solubility. The dissolution experiment was conducted on the pure drug and The similarity factor test denotes the dissolution of pure drug was dissimilar to the prepared cocrystals (F2 value 20% and 22% for 1:1 and 1:2 cocrystal). 
Stability study
Drug and cocrystals were subjected to stability study at room temperature and accelerated conditions for three months to assess the stability of cocrystals. All the The results are given in Table 2 . 
